Antibodies News and Research

RSS

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

As the number of deaths related to the pandemic H1N1 virus, commonly known as "swine flu," continues to rise, researchers have been scrambling to decipher its inner workings and explain why the incidence is lower than expected in older adults.

17 Nov 2009

Cold weather can trigger Raynaud's disease

Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack.

17 Nov 2009

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

A new study shows that molecular similarities exist between the 2009 H1N1 influenza virus and other strains of seasonal H1N1 virus that have been circulating in the population since 1988. These results suggest that healthy adults may have a level of protective immune memory that can blunt the severity of infection caused by the 2009 H1N1 influenza virus.

17 Nov 2009

FDA approves CSL's seasonal and H1N1 flu vaccines for children

The U.S. Food and Drug Administration has approved the use of the CSL Limited's seasonal and 2009 H1N1 influenza vaccines to include children ages 6 months and older. These vaccine were previously approved for use in adults, ages 18 years and older

17 Nov 2009

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

17 Nov 2009

Second Consumer Genetics Conference to be hosted at the Hynes Convention Center

The media spotlight will shine again on Boston from June 2nd – June 4th, 2010 as the Consumer Genetics Conference, (www.consumergeneticsconference.com), hosts its yearly conference at the Hynes Convention Center.

16 Nov 2009

UT physicians treat Iraqi girl with myasthenia gravis

Plagued by a growing weakness that left her unable to walk, talk and even take a normal breath, 11-year-old Iraqi Aram Ali was a shell of the bright little girl she used to be.

16 Nov 2009

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease.

16 Nov 2009

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences, a company focused on misfolded protein diseases, today reported its second quarter operating results and provided an update on the Company's diagnostic and therapeutic programs.

13 Nov 2009

PAF receives additional funding support for serving patients with multiple myeloma

Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is pleased to announce that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR).

13 Nov 2009

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

The U.S. Food and Drug Administration has approved the use of the CSL Limited's 2009 H1N1 influenza vaccine to include children ages 6 months and older. This vaccine was previously approved only for use in adults, ages 18 years and older.

13 Nov 2009

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

BioInvent International AB has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

13 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

11 Nov 2009

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics.

10 Nov 2009

Exposure to common infections may increase stroke risk

Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

10 Nov 2009

Antibodies News and Research

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

Cold weather can trigger Raynaud's disease

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

FDA approves CSL's seasonal and H1N1 flu vaccines for children

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

Second Consumer Genetics Conference to be hosted at the Hynes Convention Center

UT physicians treat Iraqi girl with myasthenia gravis

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

PAF receives additional funding support for serving patients with multiple myeloma

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

BioInvent International, Daiichi Sankyo sign licence and discovery agreement

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Lower socioeconomic status linked with inability to fight H1N1

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Exposure to common infections may increase stroke risk

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery